Publication In Proc Natl Acad Sci
PNAS202208876_proof.pdf Targets for astrocyte-based treatments of Parkinson’s disease (PD) Malin Parmara,1 Parkinson’s disease (PD) is the second most common neu- rodegenerative condition worldwide, and the number of cases is expected to rise as the population ages (1). It is defined pathologically by the loss of the dopaminergic (DA) neurons in the ventral midbrain (VM) and their projection into
